Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
22.9K
-
Shares change
-
+4.29K
-
Total reported value, excl. options
-
$908K
-
Value change
-
+$170K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$39.66
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q4 2023
2 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q4 2023.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.9K shares
of 67.8M outstanding shares and own 0.03% of the company stock.
Largest 10 shareholders include FMR LLC (7.05M shares), WELLINGTON MANAGEMENT GROUP LLP (6.48M shares), BlackRock Inc. (3.68M shares), EVENTIDE ASSET MANAGEMENT, LLC (3.63M shares), RTW INVESTMENTS, LP (3.46M shares), Polar Capital Holdings Plc (3.14M shares), VANGUARD GROUP INC (3.05M shares), Kynam Capital Management, LP (3.01M shares), Point72 Asset Management, L.P. (2.76M shares), and Bellevue Group AG (2.42M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.